Complex Civil Litigation Law Firm

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl Health To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fractyl Health between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. (“Fractyl Health” or the “Company”) (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results; (ii) accordingly, Revita’s clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort’s ability to assess Revita’s efficacy; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Lead Plaintiff Deadline: October 20, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In TaboolaTo Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Taboola between May 6, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Taboola.com Ltd. (“Taboola” or the “Company”) (NASDAQ: TBLA) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company was seeing an increase in low-quality publishers; (2) as a result, the Company would need to take an aggressive approach to exiting these low-quality publisher relationships, impacting earnings; (3) as a result, the value of the Company’s publisher relationships was overstated; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Lead Plaintiff Deadline: October 20, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AEVEX To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in AEVEX between April 17, 2026 and June 4, 2026 or otherwise acquired Aevex Class A common stock pursuant or traceable to the registration statement and prospectus (the “IPO Offering Documents”) issued in connection with Aevex’s April 17, 2026 initial public offering (“IPO”) and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AEVEX Corp. (“AEVEX” or the “Company”) (NYSE: AVEX) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose a commitment to follow a 180-day “lock-up” and therefore prevent Madison from selling its Class A common stock or converting or exchanging its Class B or LLC Units into Class A common stock for public sale until at least October 13, 2026, while simultaneously concealing a pre-arranged plan between Madison and the Underwriter Defendants to prematurely abrogate that commitment and allow for an SPO shortly after the IPO. Through that SPO, Madison would earn over $200 million and the Underwriter Defendants would share in a further $8-plus million in fees. Lead Plaintiff Deadline: October 19, 2026 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in (a)  Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 13, 2025 (the “IPO” or “Offering”); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”) and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation.  Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (1) ARD-101 was less safe than Defendants had led investors to believe; (2) accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Lead Plaintiff Deadline: October 13, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.